ProCE Banner Activity

XTEND-1: Analysis of Pain Scores in Phase III Study of Efanesoctocog Alfa Prophylaxis for Patients With Previously Treated Hemophilia A

Slideset Download
Conference Coverage

Weekly efanesoctocog alfa prophylaxis yields meaningful improvement in reduction of pain across multiple endpoints for patients with hemophilia A when switching from standard-of-care prophylaxis.

Released: December 15, 2022

Expiration: December 14, 2023

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen